Tag: NOVEL

  • Ovagen

    Synthetic hepatoprotective tripeptide bioregulator of the Khavinson ultrashort peptide class

    A synthetic tripeptide (Glu-Asp-Leu) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic bioregulator targeting hepatic and gastrointestinal gene expression, distinguished from conventional hepatoprotective agents by a proposed mechanism of direct nuclear peptide-DNA interaction and chromatin remodeling rather than receptor-mediated signal transduction.

    Abstract

    Ovagen is a synthetic tripeptide composed of L-glutamic acid, L-aspartic acid, and L-leucine (Glu-Asp-Leu; single-letter code EDL) and belongs to the Khavinson class of ultrashort peptide bioregulators developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson. The compound is classified as a liver and gastrointestinal tract bioregulator within the Cytogen (synthetic short-chain peptide) product line and is proposed to exert its biological activity through direct interaction with nuclear DNA and chromatin rather than through conventional membrane receptor signaling. The molecular weight of Ovagen is 375.37 daltons (molecular formula C15H25N3O8), a size that places it within the ultrashort peptide category (2 to 7 amino acid residues) characterized by resistance to gastrointestinal peptidase degradation, oral bioavailability without enteric coating in some formulations, and the capacity to cross cellular membranes and localize to the nucleoplasm without receptor-mediated endocytosis. The principal proposed mechanism of action involves sequence-specific binding of the EDL tripeptide to double-stranded DNA in the promoter regions of hepatocyte genes governing cell proliferation, antioxidant defense, apoptosis, and inflammatory signaling. In aged rat liver tissue, Ovagen administration has been reported to produce an approximately 18-fold increase in Ki-67 expression (a marker of cellular proliferation) and an approximately 6-fold decrease in p53 expression (a marker of apoptotic signaling and cellular senescence), suggesting a shift from senescent to proliferative hepatocyte phenotype [1, 2]. In preclinical models of chemically induced hepatotoxicity (carbon tetrachloride and paracetamol), Ovagen administration over 14 to 28 days reduced serum liver enzyme elevation, decreased hepatocyte necrosis and inflammatory cell infiltration on histological examination, and normalized hepatic antioxidant status [3, 4]. A secondary research application involves gastrointestinal mucosal support, with preclinical data suggesting that Ovagen strengthens epithelial barrier function, increases tight junction protein expression, and reduces intestinal permeability in aging models [5]. The compound has not been approved by any national regulatory authority for therapeutic use. No published, peer-reviewed human clinical trials of Ovagen exist as of the date of this monograph. The evidence base is entirely preclinical (cell culture and rodent models) and is derived predominantly from the Khavinson laboratory and collaborating Russian institutions. The peptide bioregulator framework within which Ovagen was developed has produced a substantial body of Russian-language and English-language literature, including a 2021 systematic review of peptide regulation of gene expression published in the journal Molecules [6], but the framework has not been independently validated by Western regulatory-standard clinical trials. Investigators considering Ovagen for research applications should weight the evidence accordingly, noting the predominantly single-laboratory provenance of the preclinical data, the absence of human pharmacokinetic characterization to Western regulatory standards, and the mechanistic novelty of the proposed direct peptide-DNA interaction pathway. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Vilon

    Synthetic immunomodulatory dipeptide bioregulator of thymic origin with epigenetic chromatin-remodeling activity

    A synthetic dipeptide (L-Lys-L-Glu) derived from structural analysis of the thymic polypeptide complex Thymalin, developed at the Saint Petersburg Institute of Bioregulation and Gerontology as the smallest bioactive peptide bioregulator with immunomodulatory, geroprotective, and epigenetic chromatin-reactivation activity in aging immune cells.

    Abstract

    Vilon (L-lysyl-L-glutamic acid; KE dipeptide; CAS 45234-02-4; molecular formula C11H21N3O5; molecular weight 275.30 g/mol) is a synthetic dipeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology as the minimal pharmacophore unit of the thymic polypeptide extract Thymalin. The compound represents the shortest bioactive peptide characterized in the Khavinson bioregulatory peptide class, consisting of a single lysine residue bonded to a single glutamic acid residue in the alpha-peptide linkage. Despite its minimal chain length, Vilon has demonstrated reproducible immunomodulatory, anti-tumor, geroprotective, and epigenetic activity across more than two decades of experimental investigation conducted primarily in Russian academic institutions and published in the Bulletin of Experimental Biology and Medicine, Biogerontology, Advances in Gerontology, and the International Journal of Molecular Sciences. The principal molecular mechanism, characterized by Lezhava, Khavinson, and Jokhadze in a series of cytogenetic studies from 2003 to 2023, is sequence-specific binding to the tetranucleotide motif TCGA in gene promoter regions, producing deheterochromatinization (decondensation of constitutive and facultative heterochromatin) in aging lymphocytes and thymocytes, with consequent reactivation of ribosomal genes and release of age-repressed transcriptional programs [1, 2, 3]. The immunomodulatory activity, characterized in thymic cell cultures and in the THP-1 monocyte/macrophage cell line, includes upregulation of CD4 and CD5 T-lymphocyte differentiation markers, enhancement of nucleolar organizer region associated protein expression, stimulation of interleukin-2 gene expression in blood lymphocytes, and suppression of lipopolysaccharide-induced tumor necrosis factor alpha and interleukin-6 release from terminally differentiated macrophages [4, 5, 6]. The geroprotective profile, established in female CBA mice receiving subcutaneous Vilon from 6 months of age through the lifespan, includes increased mean lifespan by approximately 24 percent, increased physical activity and endurance, decreased body temperature, and reduced incidence of spontaneous neoplasms including lung adenomas and lymphomas [7, 8]. Antitumor activity was independently confirmed in a chemically induced rat urinary bladder carcinogenesis model, where Vilon reduced tumor incidence from 75.5 percent to 56 percent and inhibited preneoplastic changes in the urothelial mucosa [9]. Pharmacokinetic data from intestinal tract and liver homogenate studies demonstrate that the KE dipeptide resists hydrolysis in small intestinal preparations and is only marginally degraded in large intestinal and hepatic preparations, supporting oral and parenteral bioavailability [13]. The compound is not approved by the United States Food and Drug Administration or by the European Medicines Agency. It is not registered as a pharmaceutical product outside the Russian Federation. Research-grade Vilon is supplied by multiple peptide synthesis vendors at greater than 98 percent purity by high-performance liquid chromatography. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cortagen

    Khavinson tetrapeptide bioregulator (Ala-Glu-Asp-Pro)

    A four-residue synthetic peptide developed by the Khavinson group as a cerebral cortex bioregulator, part of the Russian short-peptide bioregulator class.

    Abstract

    Cortagen (Ala-Glu-Asp-Pro; CAS 254749-42-7; molecular weight 414.41) is a four-residue synthetic peptide developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson as a representative of the short-peptide bioregulator class derived from cortexin (a porcine cerebral cortex extract registered as a medicine in the Russian Federation). The Khavinson program isolated active fragments from organ-specific peptide extracts and characterized synthetic tetrapeptide and tripeptide analogs as the molecular basis of the parent extract’s activity, including Cortagen for cerebral cortex, Pinealon (Glu-Asp-Arg) for pineal/CNS, Epitalon (Ala-Glu-Asp-Gly) for pineal, Vilon (Lys-Glu) for thymus, and several others. The proposed mechanism is direct DNA binding of the short peptides at promoter regions of tissue-specific genes, modulating transcription in a cell-type-restricted manner; published Russian-language work characterizes binding to specific GC-rich regulatory regions and effects on transcription factor recruitment. The Khavinson bioregulator class is registered as medicines in the Russian Federation and a small number of CIS jurisdictions; FDA, EMA, and most Western regulatory authorities have not reviewed the class. The principal limitation on the evidence base is the dominance of the originating laboratory’s publications and the limited scale of clinical evidence relative to what would be required for Western regulatory approval. Investigators should weight the evidence accordingly.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • NA-Semax Amidate

    N-acetylated and amidated Semax derivative

    An N-terminal-acetylated, C-terminal-amidated variant of the heptapeptide nootropic Semax, designed to extend plasma and central nervous system exposure beyond both the parent and the simple N-acetyl variant.

    Abstract

    NA-Semax Amidate (N-acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-NH2) is a doubly modified variant of Semax (the seven-residue ACTH(4-10) analog Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Russian Academy of Sciences as a long-acting analog. Semax itself is registered in the Russian Federation as an intranasal nootropic and stroke treatment at 0.1 percent and 1 percent solutions, with a published pharmacological signature of BDNF and NGF transcriptional upregulation, neuroprotection in middle cerebral artery occlusion stroke models, and pro-cognitive effects in passive avoidance and operant conditioning paradigms. The parent Semax has a plasma half-life of minutes and a central nervous system exposure window of similarly short duration after intranasal administration. The N-acetyl variant of Semax (NA-Semax) extends plasma half-life by approximately 5-fold by blocking the aminopeptidase cleavage at the methionine N-terminus, and the C-terminal amidation in the Amidate variant additionally blocks the carboxypeptidase cleavage at the proline C-terminus, producing a peptide with the longest exposure in the Semax family. Comparative pharmacology in rodent models reports that NA-Semax Amidate at one-tenth the dose of parent Semax produces equivalent or greater BDNF mRNA elevation in cortex and hippocampus and equivalent neuroprotection in stroke models, with substantially longer duration of effect. Routes studied include subcutaneous, intramuscular, intranasal, and intraperitoneal administration. The compound is research-grade and not approved by any regulatory authority; the principal published record is in Russian-language journals from the Institute of Molecular Genetics RAS. Investigators should treat the extended-PK variant as a research tool for studying long-duration ACTH-derived heptapeptide pharmacology where the brief pulse from intranasal Semax is operationally limiting.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Pancragen

    Synthetic tetrapeptide bioregulator of pancreatic endocrine and exocrine cell differentiation and function

    A synthetic tetrapeptide (Lys-Glu-Asp-Trp) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic modulator of pancreatic cell differentiation, glucose homeostasis, and beta cell functional recovery in aging and type 2 diabetes mellitus.

    Abstract

    Pancragen (Lys-Glu-Asp-Trp-NH2; KEDW) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology (Russia) as a tissue-specific modulator of pancreatic endocrine and exocrine cell differentiation and function. The compound belongs to the Khavinson class of ultrashort (two to four amino acid) bioregulatory peptides, a pharmacological category defined by the hypothesis that short peptides penetrate cell nuclei, bind complementary DNA sequences in promoter regions through electrostatic and hydrogen-bond interactions, and modulate gene expression in a tissue-specific manner without engaging classical cell-surface receptors. Pancragen was derived from fractionation of bovine pancreatic tissue extracts; the tetrapeptide Lys-Glu-Asp-Trp was identified as the minimal active sequence responsible for the pancreotrophic activity of the parent extract preparation Suprefort. The compound has a molecular formula of C26H36N6O9 (free acid form) and a molecular weight of 576.60 g/mol. Physical-chemical characterization by ultraviolet-visible absorption spectroscopy, circular dichroism, and molecular modeling has demonstrated that the KEDW tetrapeptide binds double-stranded DNA in the major groove at sequences containing the ACCT motif, which is found in promoter regions of genes responsible for pancreatic cell differentiation and function [1]. The principal downstream molecular consequence of this interaction is upregulation of transcription factors that govern pancreatic endocrine cell fate, including PDX1 (the earliest marker of pancreatic progenitor cells and the master regulator of beta cell identity), NGN3, PAX6, PAX4, FOXA2, NKX2-2, and NKX6.1 [2, 3]. In organotypic pancreatic cell cultures from young and aged rats, Pancragen stimulated the expression of differentiation factors of both acinar cells (Pdx1, Ptf1a) and islet of Langerhans cells (Pdx1, Pax6, Pax4, Foxa2, Nkx2.2), with the inducing effect more pronounced in aged cultures, consistent with a geroprotective mechanism [3]. Preclinical pharmacology in streptozotocin-induced diabetic rats demonstrated that oral Pancragen produced a pronounced hypoglycemic effect during the treatment period and that intramuscular administration normalized the adhesion properties of mesenteric capillary endothelium without modifying capillary permeability, suggesting homeostatic and endothelioprotective activity in early diabetes [4]. In a study of biological activity using immunoenzyme and high-performance liquid chromatography methods, the tetrapeptide modulated metabolic parameters characterizing apoptosis, including caspase-3 activity, in pancreatic beta cells and hepatocytes from streptozotocin-treated animals [5]. A comparative study in the same primate model demonstrated that Pancragen normalized insulin and C-peptide levels (suggesting recovery of disturbed glucose tolerance) while glimepiride produced a stronger but delayed blood-glucose-lowering effect without substantially affecting insulin secretion, indicating mechanistically distinct activity [7]. In a clinical study of 33 elderly patients with type 2 diabetes mellitus, Pancragen administered against a background of constant-dose glibenclamide significantly decreased fasting plasma glucose and glucose concentrations at two hours during oral glucose tolerance testing, reduced plasma insulin levels, and decreased the HOMA insulin resistance index; an additional glucose-lowering effect persisted for two weeks after cessation of Pancragen in 60 percent of patients who continued glibenclamide at unchanged doses [8]. Organotypic tissue culture studies confirmed that Pancragen at concentrations as low as 0.05 ng/mL stimulated tissue growth in pancreatic explants from both young and aged rats, with the stimulating effect tissue-specific (no effect on non-pancreatic tissue explants at the same concentration) [9]. The compound has not been approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is marketed in Russia as a dietary supplement (Pancragen capsules) and is available internationally as a research-grade peptide from multiple suppliers. Formal toxicology studies meeting International Council for Harmonisation or FDA regulatory standards have not been published. The existing safety data, derived exclusively from the Khavinson research network, report no significant adverse events in preclinical or clinical studies at the doses and durations studied. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Davunetide (NAP)

    ADNP-derived octapeptide

    An eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) studied in tauopathies and PSP.

    Abstract

    Davunetide (NAP, AL-108; Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; CAS 173308-60-2; molecular weight 824.94) is an octapeptide derived from activity-dependent neuroprotective protein (ADNP). The peptide preserves microtubule integrity and reduces tau pathology in animal models of tauopathy. Davunetide was developed by Allon Therapeutics and advanced through Phase 2/3 trials in progressive supranuclear palsy (PSP); the pivotal trial in 2012 was negative for the primary cognitive endpoint, ending the development program. The compound is administered intranasally (the primary route of delivery to CNS for the formulation used in trials).

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Sulbutiamine

    Synthetic disulfide thiamine derivative

    A lipophilic disulfide thiamine analog that crosses the blood-brain barrier; developed in Japan for asthenia and used as a nootropic.

    Abstract

    Sulbutiamine (isobutyryl thiamine disulfide; CAS 3286-46-2; molecular formula C32H46N8O6S2; molecular weight 702.89) is a synthetic disulfide derivative of thiamine (vitamin B1) developed in Japan in the 1960s and approved in several Asian and European markets under the trade name Arcalion. The compound is structurally a dimer of two thiamine molecules joined by a disulfide bridge, conferring high lipophilicity and improved blood-brain barrier penetration compared to thiamine itself. Mechanism: thiamine prodrug; sulbutiamine is metabolized to thiamine in the brain, raising central thiamine concentrations and supporting thiamine-dependent enzymes (transketolase, pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase). Clinical use is in psychogenic asthenia and as a nootropic; evidence is from clinical trials with mixed methodology. Plasma half-life is approximately 5 hours. Used as a lipophilic thiamine prodrug in research and nootropic communities.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • ARA-290 (Cibinetide)

    EPO-derived helix B peptide

    An 11-amino-acid fragment of erythropoietin’s helix B with tissue-protective activity but without erythropoietic activity.

    Abstract

    ARA-290 (Cibinetide; Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; CAS 1208243-50-8) is an 11-residue peptide derived from the alpha-helix B region of erythropoietin (EPO). The peptide retains the tissue-protective and anti-inflammatory activity of EPO (mediated through the heteromeric EPO/CD131 innate repair receptor) without the erythropoietic activity (mediated through the EPO receptor homodimer). The compound was developed by Araim Pharmaceuticals for diabetic neuropathy, sarcoidosis-associated small fiber neuropathy, and other neuropathic pain indications. Phase 2 trials in sarcoidosis-associated SFN showed reductions in neuropathic pain and improvements in autonomic measures.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Thymulin

    Zinc-dependent thymic nonapeptide

    A zinc-dependent endogenous thymic nonapeptide secreted by thymic epithelial cells with T-cell maturation activity.

    Abstract

    Thymulin (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn; molecular weight 857) is a nonapeptide originally isolated by Bach and Goldstein groups in the 1970s. The peptide is endogenously secreted by thymic epithelial cells and requires bound zinc for biological activity. Pharmacology includes promotion of T-cell differentiation, modulation of cytokine balance, and effects on autoimmune and inflammatory processes. The compound has been studied in chronic infections, autoimmune diseases, and cancer immunotherapy adjunct applications, with limited Phase 2 evidence. Available as research peptide.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Latrepirdine (Dimebon)

    Multi-target antihistamine / mitochondrial protectant

    A Russian antihistamine repurposed for Alzheimer disease and Huntington disease; phase 3 trials failed despite encouraging phase 2 results.

    Abstract

    Latrepirdine (Dimebon, dimebolin; CAS 3613-73-8; molecular formula C21H25N3; molecular weight 319.45) is a tetrahydro-gamma-carboline antihistamine developed in the USSR in the 1960s and approved in Russia for allergic conditions. The compound is a non-selective receptor blocker (H1, alpha-1, alpha-2, 5-HT2A, 5-HT5A, 5-HT6, D1, D2). The Alzheimer disease application emerged from drug repurposing screens in the 2000s; preclinical studies suggested mitochondrial protective effects independent of the receptor binding. Phase 2 trial in mild-to-moderate Alzheimer disease (2008) demonstrated significant improvement in ADAS-cog and other endpoints, generating widespread interest. Phase 3 trials (CONNECTION, CONCERT) in 2010-2012 failed to replicate the phase 2 effects, marking one of the highest-profile late-stage failures in CNS drug development. The compound is no longer in clinical development. Used as a research compound for multi-target receptor pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.